Skye Bioscience, Inc. cotiza a 1.58 USD y tiene una capitalización bursátil de $7M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoi…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.32 | $-0.37 | $-0.32 |
| Estimado | $-0.26 | $-0.32 | $-0.31 | $-0.32 |
| Sorpresa | — | +0.0% | -19.4% | +0.0% |
| Métrica | SKYE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -279.3% | -40.4% | -238.9% |
| ROA | -197.5% | -32.0% | -165.5% |
| Current Ratio | 3.30 | 2.84 | +0.46 |
| Debt / Equity | — | 0.28 | — |